Comparison of first-generation EGFR-TKIs combined with low-dose bevacizumab versus osimertinib in untreated advanced EGFR-mutated NSCLC
Background This study aimed to compare the efficacy of first-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) combined with low-dose bevacizumab(7.5 mg/kg) versus osimertinib as first-line treatment in patients with advanced EGFR-mutated non-small cell lung cancer...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2025-12-01
|
| Series: | Annals of Medicine |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/07853890.2025.2493766 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850144622931607552 |
|---|---|
| author | Yingqi Xu Yidan Zhang Hongping Jin Hua Zhong Jianlin Xu Yuqing Lou Runbo Zhong |
| author_facet | Yingqi Xu Yidan Zhang Hongping Jin Hua Zhong Jianlin Xu Yuqing Lou Runbo Zhong |
| author_sort | Yingqi Xu |
| collection | DOAJ |
| description | Background This study aimed to compare the efficacy of first-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) combined with low-dose bevacizumab(7.5 mg/kg) versus osimertinib as first-line treatment in patients with advanced EGFR-mutated non-small cell lung cancer (NSCLC).Materials and methods A total of 161 patients with advanced NSCLC harboring EGFR mutations, who received first-line treatment at Shanghai Chest Hospital between July 2017 and July 2023, were enrolled in this study. Among them, 78 patients were treated with a combination of first-generation EGFR-TKIs and bevacizumab (7.5 mg/kg), constituting the bevacizumab plus TKI (A + T) group. The remaining 83 patients received osimertinib monotherapy (80 mg daily), forming the osimertinib group.Results The objective response rate (ORR) was 65.4% (51/78) in the A + T group and 68.7% (57/83) in the osimertinib group (p = 0.657). Despite the potentially poorer baseline conditions of patients in the osimertinib group, the median progression-free survival (PFS) was 16.59 months (95% CI: 14.39–18.80) in the A + T group compared to 16.82 months (95% CI: 13.76–19.89) in the osimertinib group (p = 0.792). Preliminary overall survival (OS) analysis indicated a median OS of 51.75 months (95% CI: 41.63–61.86) in the A + T group versus 35.55 months (95% CI: 22.32–48.77) in the osimertinib group (p = 0.010), however, the OS data are not yet mature.Conclusion Although osimertinib remains the preferred first-line treatment for advanced NSCLC with EGFR mutations, combining first-generation EGFR-TKIs with low-dose bevacizumab may be a viable alternative for certain patients. |
| format | Article |
| id | doaj-art-439023e2b8fa4c448fecdbabd69b7623 |
| institution | OA Journals |
| issn | 0785-3890 1365-2060 |
| language | English |
| publishDate | 2025-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Annals of Medicine |
| spelling | doaj-art-439023e2b8fa4c448fecdbabd69b76232025-08-20T02:28:19ZengTaylor & Francis GroupAnnals of Medicine0785-38901365-20602025-12-0157110.1080/07853890.2025.2493766Comparison of first-generation EGFR-TKIs combined with low-dose bevacizumab versus osimertinib in untreated advanced EGFR-mutated NSCLCYingqi Xu0Yidan Zhang1Hongping Jin2Hua Zhong3Jianlin Xu4Yuqing Lou5Runbo Zhong6Department of Respiratory and Critical Care Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaDepartment of Respiratory and Critical Care Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaDepartment of Respiratory and Critical Care Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaDepartment of Respiratory and Critical Care Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaDepartment of Respiratory and Critical Care Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaDepartment of Respiratory and Critical Care Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaDepartment of Respiratory and Critical Care Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaBackground This study aimed to compare the efficacy of first-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) combined with low-dose bevacizumab(7.5 mg/kg) versus osimertinib as first-line treatment in patients with advanced EGFR-mutated non-small cell lung cancer (NSCLC).Materials and methods A total of 161 patients with advanced NSCLC harboring EGFR mutations, who received first-line treatment at Shanghai Chest Hospital between July 2017 and July 2023, were enrolled in this study. Among them, 78 patients were treated with a combination of first-generation EGFR-TKIs and bevacizumab (7.5 mg/kg), constituting the bevacizumab plus TKI (A + T) group. The remaining 83 patients received osimertinib monotherapy (80 mg daily), forming the osimertinib group.Results The objective response rate (ORR) was 65.4% (51/78) in the A + T group and 68.7% (57/83) in the osimertinib group (p = 0.657). Despite the potentially poorer baseline conditions of patients in the osimertinib group, the median progression-free survival (PFS) was 16.59 months (95% CI: 14.39–18.80) in the A + T group compared to 16.82 months (95% CI: 13.76–19.89) in the osimertinib group (p = 0.792). Preliminary overall survival (OS) analysis indicated a median OS of 51.75 months (95% CI: 41.63–61.86) in the A + T group versus 35.55 months (95% CI: 22.32–48.77) in the osimertinib group (p = 0.010), however, the OS data are not yet mature.Conclusion Although osimertinib remains the preferred first-line treatment for advanced NSCLC with EGFR mutations, combining first-generation EGFR-TKIs with low-dose bevacizumab may be a viable alternative for certain patients.https://www.tandfonline.com/doi/10.1080/07853890.2025.2493766BevazicumabEGFR-TKIlow-doseNSCLCosimertinib |
| spellingShingle | Yingqi Xu Yidan Zhang Hongping Jin Hua Zhong Jianlin Xu Yuqing Lou Runbo Zhong Comparison of first-generation EGFR-TKIs combined with low-dose bevacizumab versus osimertinib in untreated advanced EGFR-mutated NSCLC Annals of Medicine Bevazicumab EGFR-TKI low-dose NSCLC osimertinib |
| title | Comparison of first-generation EGFR-TKIs combined with low-dose bevacizumab versus osimertinib in untreated advanced EGFR-mutated NSCLC |
| title_full | Comparison of first-generation EGFR-TKIs combined with low-dose bevacizumab versus osimertinib in untreated advanced EGFR-mutated NSCLC |
| title_fullStr | Comparison of first-generation EGFR-TKIs combined with low-dose bevacizumab versus osimertinib in untreated advanced EGFR-mutated NSCLC |
| title_full_unstemmed | Comparison of first-generation EGFR-TKIs combined with low-dose bevacizumab versus osimertinib in untreated advanced EGFR-mutated NSCLC |
| title_short | Comparison of first-generation EGFR-TKIs combined with low-dose bevacizumab versus osimertinib in untreated advanced EGFR-mutated NSCLC |
| title_sort | comparison of first generation egfr tkis combined with low dose bevacizumab versus osimertinib in untreated advanced egfr mutated nsclc |
| topic | Bevazicumab EGFR-TKI low-dose NSCLC osimertinib |
| url | https://www.tandfonline.com/doi/10.1080/07853890.2025.2493766 |
| work_keys_str_mv | AT yingqixu comparisonoffirstgenerationegfrtkiscombinedwithlowdosebevacizumabversusosimertinibinuntreatedadvancedegfrmutatednsclc AT yidanzhang comparisonoffirstgenerationegfrtkiscombinedwithlowdosebevacizumabversusosimertinibinuntreatedadvancedegfrmutatednsclc AT hongpingjin comparisonoffirstgenerationegfrtkiscombinedwithlowdosebevacizumabversusosimertinibinuntreatedadvancedegfrmutatednsclc AT huazhong comparisonoffirstgenerationegfrtkiscombinedwithlowdosebevacizumabversusosimertinibinuntreatedadvancedegfrmutatednsclc AT jianlinxu comparisonoffirstgenerationegfrtkiscombinedwithlowdosebevacizumabversusosimertinibinuntreatedadvancedegfrmutatednsclc AT yuqinglou comparisonoffirstgenerationegfrtkiscombinedwithlowdosebevacizumabversusosimertinibinuntreatedadvancedegfrmutatednsclc AT runbozhong comparisonoffirstgenerationegfrtkiscombinedwithlowdosebevacizumabversusosimertinibinuntreatedadvancedegfrmutatednsclc |